Expertise in
27
conditions

Dr. James J. Urbanic

Radiation Oncology
Office
1200 Garden View Rd Ste 210, 
Encinitas, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
27
conditions
Office
1200 Garden View Rd Ste 210, 
Encinitas, CA 

Overview

James Urbanic is a Radiation Oncologist practicing medicine in Encinitas, California.

Dr. Urbanic is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Anal Cancer, Pleuropulmonary Blastoma, Pancreaticoduodenectomy, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 8 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NC

Hospital Affiliations

Tri-City Medical Center
Uc San Diego Health Hillcrest - Hillcrest Med Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
1200 Garden View Rd Ste 210, Encinitas, CA 92024

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Enrollment Status: Recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Tempol
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Radiation
Study Phase: Phase 1
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II Biomarker Study of Restriction Spectrum Imaging (RSI) MRI in Patients With High-Risk, Localized Prostate Cancer Who Will Receive Radiotherapy and Androgen Deprivation Therapy
A Phase II Biomarker Study of Restriction Spectrum Imaging (RSI) MRI in Patients With High-Risk, Localized Prostate Cancer Who Will Receive Radiotherapy and Androgen Deprivation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

64 Total Publications

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.
Journal: Clinical and translational radiation oncology
Published: April 26, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Jyoti S. Mayadev
Radiation Oncology
Expertise in
8
conditions
Dr. Jyoti S. Mayadev
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (12.6 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jyoti Mayadev is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Mayadev is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Vulvar Cancer, Neuroendocrine Carcinoma of the Cervix, Endometrial Cancer, and Lymphadenectomy.

Expertise in
21
conditions
Dr. Jona A. Hattangadi-Gluth
Radiation Oncology
Expertise in
21
conditions
Dr. Jona A. Hattangadi-Gluth
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (12.6 miles away)
858-822-6040
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jona Hattangadi-Gluth is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Hattangadi-Gluth is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Brain Tumor, Arteriovenous Malformation, Vein of Galen Aneurysm, and Wyburn-Mason Syndrome.

Expertise in
8
conditions
Dr. Brent S. Rose
Radiation Oncology
Expertise in
8
conditions
Dr. Brent S. Rose
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (12.6 miles away)
619-341-3899
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brent Rose is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Rose is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Anal Cancer, Prostatectomy, and Orchiectomy.

Frequently Asked Questions about Dr. James J. Urbanic

How do I make an appointment with Dr. James J. Urbanic?

You can book an appointment with Dr. James J. Urbanic by calling their office at 858-246-0500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James J. Urbanic a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James J. Urbanic is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James J. Urbanic specialize in?

While Dr. James J. Urbanic is a Radiation Oncology, they have specific expertise in Lung Cancer, Anal Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. James J. Urbanic participate in research or clinical trials?

Yes. Dr. James J. Urbanic has published 64 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. James J. Urbanic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James J. Urbanic accept my insurance?

Dr. James J. Urbanic accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 858-246-0500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Urbanic's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile